Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis

Advances in Experimental Medicine and Biology

Volumn 728, Issue , 2012, Pages 65-83

  Martin, Aline ^a   Quarles, L Darryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; FIBROBLAST GROWTH FACTOR; PHOSPHATE; VITAMIN D;

ARTICLE; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIC RICKETS; BONE DYSPLASIA; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; GENETIC DISORDER; HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; MINERAL METABOLISM; MUSCULOSKELETAL FUNCTION; NONHUMAN; OSTEOGLOPHONIC DYSPLASIA; PARATHYROID FUNCTION; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; VITAMIN D METABOLISM; X LINKED HYPOPHOSPHATEMIC RICKETS; ANIMAL; BONE; GENETICS; HOMEOSTASIS; KIDNEY; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; KIDNEY; PHOSPHATES; VITAMIN D;

EID: 84859536721     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0887-1_4     Document Type: Article

References (114)

1. Quarles LD. Endocrine functions ofbone in mineral metabolism regulation. J Clin Invest2008;118(12):3820-8
2. Rizzoli R, Fleisch H, Bonjour JP. Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply. J Clin Invest 1977; 60(3):639-47
3. Talmage RV, Doppelt SH, Fondren FB. An interpretation of acute changes in plasma 45Ca following parathyroid hormone administration to thyroparathyroidectomized rats. CalcifTissue Res 1976; 22(2):117-28
4. Ma YL, Cain RL, Halladay DL et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology2001; 142(9):4047-54
5. Shiraki M, Gee MV, Baum BJ et al. Parathyroid hormone stimulates phosphate efflux through an apparently adenosine 3′,5′- monophosphate-independent process in rat parotid cell aggregates. Endocrinology 1986; 118(5):2009-15
6. Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 2009; 310(1-2):21-9
7. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277(2):494-8
8. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20(11):563-9
9. ItohN, Ornitz DM. Functional evolutionary history ofthe mouse Fgfgene family. Dev Dyn2008; 237(1):18-27
10. Suzuki M, Uehara Y, Motomura-Matsuzaka K et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008; 22(4):1006-14
11. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281(10):6120-3
12. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444(7120):770-4
13. Yu X, Ibrahimi OA, Goetz R et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146(11):4647-56
14. Li SA, Watanabe M, Yamada H et al. Immunohistochemical localization of Klotho protein in brain, kidney and reproductive organs of mice. Cell Struct Funct 2004; 29(4):91-9
15. Yamazaki Y, Tamada T, Kasai N et al.. Anti-FGF23 neutralizing antibodies show the physiological role and structural features ofFGF23. J Bone Miner Res 2008; 23(9):1509-18
16. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; l7(5):l305-l5
17. Bai X, Miao D, Li J et al. Transgenic mice overexpressing human fibroblast growth factor 23 (Rl76Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; l45(ll):5269-79
18. Larsson T, Marsell R, Schipani E et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alphal(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphatehomeostasis. Endocrinology2004; l45(7):3087-94
19. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad SciUSA200l;98(ll):6500-5
20. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289(5):Fl088-95
21. Saito H, Kusano K, Kinosaki M. Human fibroblast growth factor-23 mutants suppressNa+-dependent phosphate cotransport activity and lalpha,25- dihydroxyvitamin D3 production. J Biol Chem 2003; 278(4):2206-ll
22. Zhang F, Zhai G, Kato BS et al. Association between KLOTHO gene and hand osteoarthritis in a female Caucasian population. Osteoarthritis Cartilage, 2007
23. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature l997; 390(6655):45-5l
24. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; ll7(l2):4003-8
25. Wang H, Yoshiko Y, Yamamoto R et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008; 23(6):939-48
26. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 29l(l):E38-49
27. Shimada T, Kakitani M, Yamazaki Y etal. Targeted ablation ofFgf23 demonstrates an essential physiological role ofFGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; ll3(4):56l-8
28. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23(7):42l-32
29. Hesse M, Frohlich LF, Zeitz U et al. Ablation of vitamin D signaling rescues bone, mineral and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol2007; 26(2):75-84
30. Sitara D, Razzaque MS, St-Arnaud R et al. Genetic ablation of vitamin d activation pathway reverses biochemical and skeletal anomalies in fgf-23-null animals. Am J Pathol 2006; l69(6):2l6l-70
31. Stubbs J, Liu S, Tang W et al. Role of Hyperphosphatemia and l,25(OH2D3 in Vascular Calcifications and Mortality in FGF23 Null Mice. J Am Soc Nephrol 2007; 17:689a
32. Brownstein CA, Adler F, Nelson-Williams C et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 2008; l05(9):3455-60
33. Bai XY, Miao D, Goltzman D et al. The autosomal dominant hypophosphatemic rickets Rl76Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem2003; 278(ll):9843-9
34. Benet-Pages A, Lorenz-Depiereux B, Zischka H et al. FGF23 is processed by proprotein convertases but notby PHEX. Bone 2004; 35(2):455-62
35. Feng JQ, Ward LM, Liu S et al. Loss of DMPl causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38(ll):l3l0-5
36. Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al. DMPl mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006;38(ll):l248-50
37. Ling Y, Rios HF, Myers ER et al. DMPl depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res 2005; 20(l2):2l69-77
38. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348(l7):l656-63
39. Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; l8(7):l227-34
40. Berndt T, Craig TA, Bowe AE et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003; ll2(5):785-94
41. Guo R, Quarles LD. Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts. J Bone Miner Res l997; l2(7):l009-l7
42. The HYP Consortium, A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemicrickets. NatGenet l995; ll (2):l30-6
43. Thompson DL, Sabbagh Y, Tenenhouse HS et al. Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. J Bone Miner Res 2002; l7(2):3ll-20
44. Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278(39):374l9-26
45. White KE, Cabral JM, Davis SI et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFRl in bone elongation. Am J Hum Genet 2005; 76(2):36l-7
46. Benet-Pages A, Orlik P, Strom TM et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; l4(3):385-90
47. Larsson T, Davis SI, Garringer HJ et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 2005; l46(9):3883-9l
48. Lyles KW, Burkes EJ, Ellis GJ et al. Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. J Clin Endocrinol Metab l985; 60(6):l093-6
49. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; ll7(9):2684-269l
50. Topaz O, Indelman M, Chefetz I et al. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet 2006; 79(4):759-64
51. Bennett EP, Hassan H, Clausen H. cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N- acetylgalactosaminyltransferase, GalNAc-t3. J Biol Chem l996; 27l(29):l7006-l2
52. Segawa H, Yamanaka S, Ohno Y et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 2007; 292(2):F769-79
53. Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of l,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal lalpha-hydroxylase gene. Endocrinology2002; l43(2):683-9
54. Razzaque MS, Sitara D, Taguchi T et al. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006; 20(6):720-2
55. Amanzadeh J, Reilly RF, Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006; 2(3):l36-48
56. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; l5(8):2208-l8
57. Masuyama R, Stockmans I, Torrekens S et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006; ll6(l2):3l50-9
58. Samadfam R, Richard C, Nguyen-Yamamoto L et al. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009; l50(ll):4835-45
59. Tebben PJ, Singh RJ, Clarke BL et al. Fibroblast growth factor 23, parathyroid hormone and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 2004; 79(l2):l508-l3
60. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; l8(l0):2683-8
61. Saji F, Shiizaki K, Shimada S et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol 2009; lll(4):p59-66
62. Perwad F, Azam N, Zhang MY et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and l,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005; l46(l2):5358-64
63. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90(3):l5l9-24
64. Nishida Y, Taketani Y, Yamanaka-Okumura H et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006; 70(l2):2l4l-7
65. Domrongkitchaiporn S, Disthabanchong S, Cheawchanthanakij R et al. Oral phosphate supplementation corrects hypophosphatemia and normalizes plasma FGF23 and 25-hydroxyvitamin D3 levels in women with chronic metabolic acidosis. Exp Clin Endocrinol Diabetes 20l0; ll8(2):l05-l2
66. Prentice A, Ceesay M, Nigdikar Setal. FGF23 is elevated in Gambian children with rickets. Bone 2008; 42(4):788-97
67. van Boekel G, Ruinemans-Koerts J, Joosten F et al. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol 2008; l58(3):43l-7
68. Rowe PS, Kumagai Y, Gutierrez G et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004; 34(2):303-l9
69. Liu S, Rowe PS, Vierthaler L et al. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007; l92(l):26l-7
70. Yuan B, Takaiwa M, Clemens TL et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 2008; ll8(2):722-34
71. Bowe AE, Finnegan R, Jan de Beur SM et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 200l; 284(4):977-8l
72. Guo R, Liu S, Spurney RF et al. Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 200l; 28l(4):E837-47
73. Campos M, Couture C, Hirata IY et al. Human recombinant endopeptidase PHEX has a strict Sl′ specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 2003; 373(Pt l):27l-9
74. Addison WN, Nakano Y, Loisel T et al. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 2008; 23(l0):l638-49
75. Martin A, David V, Laurence JS etal. Degradation ofMEPE, DMPl andrelease ofSIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008; l49(4):l757-72
76. Liu S, Brown TA, Zhou J et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005; l6(6):l645-53
77. Bai X, Miao D, Panda D et al. Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 2002; l6(l2):29l3-25
78. Erben RG, Mayer D, Weber K et al. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Miner Res 2005; 20(7):ll49-60
79. Liu S, Guo R, Tu Q et al. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 2002; 277(5):3686-97
80. Feng JQ, Ward LM, Liu S et al. Loss of DMPl causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet, 2006
81. Narayanan K, Ramachandran A, Hao J et al. Dual functional roles of dentin matrix protein l. Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store. J Biol Chem 2003; 278(l9):l7500-8
82. Ogbureke KU, Fisher LW. Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 2004; 83(9):664-70
83. Goebel S, Lienau J, Rammoser Uetal. FGF23 is aputative marker for bone healing and regeneration. J Orthop Res 2009
84. Lu Y, Qin C, Xie Y et al. Studies of the DMPl 57-kDa functional domain both in vivo and in vitro. Cells Tissues Organs 2009; l89(l-4):l75-85
85. Liu S, Tang W, Zhou J et al. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 2008 Aug;295(2):E254-6l
86. Xiao ZS, Crenshaw M, Guo R et al. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol l998; 275(4 Pt l):E700-8
87. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Dmpl-null mice. Am J Physiol Endocrinol Metab 2008; 295(2):E254-6l
88. Liu S, Zhou J, Tang W et al. Pathogenic Role ofFgf23 in Dmpl Null Mice. Am J Physiol Endocrinol Metab, 2008
89. Marie PJ, Travers R, Glorieux FH. Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse. Calcif Tissue Int l982; 34(2):l58-64
90. Sitara D, Kim S, Razzaque MS et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008; 4(8):el000l54
91. Liu S, Vierthaler L, Tang W et al. FGFR3 and 4 do not mediate renal effectso of FGF23 in vivo. J Am Soc Nephrol 2008; In Press
92. He G, George A. Dentin matrix protein l immobilized on type I collagen fibrils facilitates apatite deposition in vitro. J Biol Chem 2004; 279(l2):ll649-56
93. Rowe PS, Matsumoto N, Jo OD et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone, 2006
94. Laize V, Martel P, Viegas CS et al. Evolution of matrix and bone gamma-carboxyglutamic acid proteins in vertebrates. J Biol Chem 2005; 280(29):26659-68
95. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature l997; 386(6620):78-8l
96. Gopalakrishnan R, Suttamanatwong S, Carlson AE et al. Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization. Cells Tissues Organs 2005; l8l(3-4):l66-75
97. Narouz-Ott L, Maurer P, Nitshce DP et al. Thrombospondin-4 binds specifically to both collagenous and noncollagenous extracellular matrix proteins via its C-terminal domains. J Biol Chem 2000; 275(47):37ll0-7
98. Posey KL, Hankenson K, Veerisetty AC et al. Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-l, thrombospondin-3, thrombospondin-5 and type IX collagen. Am J Pathol 2008; l72(6):l664-74
99. Hankenson KD, Hormuzdi SG, Meganck JA et al. Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties ofbone and have accelerated development of the femoral head. Mol Cell Biol 2005; 25(l3):5599-606
100. Ueno A, Miwa Y, Miyoshi K et al. Constitutive expression ofthrombospondin l inMC3T3-El osteoblastic cells inhibits mineralization. J Cell Physiol 2006; 209(2):322-32
101. Venta PJ, Welty RJ, Johnson TM et al. Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (l07 His-Tyr): complete structure of the normal human CAII gene. Am J Hum Genet l99l; 49(5):l082-90
102. Mori S, Wu CY, Yamaji S et al. Direct binding of integrin alphavbeta3 to FGFl plays a role in FGFl signaling. J Biol Chem 2008; 283(26):l8066-75
103. Guo R, Rowe PS, Liu S et al. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 2002; 297(l):38-45
104. Rowe PS, Garrett IR, Schwarz PM et al. Surface Plasmon Resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 2005; 36(l):33-46
105. Lu Y, Ye L, Yu S et al. Rescue of odontogenesis in Dmpl-deficient mice by targeted re-expression of DMPl reveals roles for DMPl in early odontogenesis and dentin apposition in vivo. Dev Biol 2007; 303(l):l9l-20l
106. Fang MA, Glackin CA, Sadhu A et al. Transcriptional regulation of alpha 2(I) collagen gene expression by fibroblast growth factor-2 in MC3T3-El osteoblast-like cells. J Cell Biochem 200l; 80(4):550-9
107. Nauman EA, Sakata T, Keaveny TM et al. bFGF administration lowers the phosphate threshold for mineralization in bone marrow stromal cells. Calcif Tissue Int 2003; 73(2):l47-52
108. Carpenter TO, Ellis BK, Insogna KL et al. FGF7-an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab, 2004
109. Laroche M, Boyer JF, Jahafar H et al. Normal FGF23 levels in adult idiopathic phosphate diabetes. Calcif Tissue Int 2009; 84(2):ll2-7
110. Riminucci M, Collins MT, Fedarko NS etal. FGF-23 in fibrous dysplasia ofbone and its relationship to renal phosphate wasting. J Clin Invest 2003; ll2(5):683-92
111. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; l6(7):2205-l5
112. Bahrami A, Weiss SW, Montgomery E et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 2009; 33(9):l348-54
113. Rhee Y. FGF23 gene expression is upregulated by PTH receptor activation in osteocytes in vitro and in vivo: a parathyroid-bone link influencing the endocrine function of osteocytes. J Bone Miner Res 2009; 24(Suppl l)
114. Seeman E. Bone modeling and remodeling. Crit Rev Eukaryot Gene Expr 2009; l9(3):2l9-33